Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease - Wikidata - wikimedia - TriplyDB

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

http://www.wikidata.org/entity/Q22241424

about

Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's disease New immunological approaches in treating and diagnosing CNS diseases New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs 'Clinical trials in Alzheimer's disease': immunotherapy approaches IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology The Government's role in regulating, coordinating, and standardizing the response to Alzheimer's disease: Anticipated international cooperation in the area of intractable and rare diseases Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies Progress in Alzheimer's disease.Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults.Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.Current and future treatments for Alzheimer's disease A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brain Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.Disease-modifying treatments for Alzheimer's disease.ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects Advances in tau-based drug discovery.Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.Drug development for Alzheimer's disease: recent progress IgG Conformer's Binding to Amyloidogenic Aggregates.Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease Molecular biomarkers in glaucoma Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies.Antibody-based therapy in Alzheimer's disease.Therapeutic potential of vaccines for Alzheimer's disease.Therapeutic applications of antibodies in non-infectious neurodegenerative diseases Solanezumab for Alzheimer's disease.Pharmacological treatment of Alzheimer disease.Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.Clinical applications of immunoglobulin: update.Potential sources of interference on Abeta immunoassays in biological samples Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target.Immunomodulation and AD--down but not out.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.

P2860

Q24197852-4093989A-E506-4A9D-B80E-DDA68BCCEF7B Q26865204-454DDFAC-07B4-466D-ACE5-3257AA15932E Q26866006-59CA58D0-BCAC-4C87-A789-D7E7BDCAC1A7 Q27008979-CD502FD2-27C5-4765-BA88-D0C8A8A2F987 Q27497796-0DEB207C-B6E4-4A60-8E50-87AA4926651E Q28072842-7892C325-C2DB-48D9-ABEE-1FE4AE160E5C Q28748498-7DC45C11-DB13-4417-AEA6-92208C3B76C3 Q33943357-00881716-E4B6-40C1-9128-A85BCC0DAD92 Q34274025-BB817C32-EEA7-4430-8FE1-C38D9A7E2F4A Q34408888-75419950-486F-47AD-978D-E815B65F091C Q34413715-6B473AD7-15C5-48D8-911E-E28F3432D03B Q34500145-C0F78F78-6F0A-4EA7-AB5D-D0F33056C9E2 Q34646921-F928D771-221C-4316-896E-B4009E5BADCB Q34666433-14DC4261-F068-46D5-9E2E-57B6584EA02B Q34733689-D210484E-3E86-4A6F-BB70-9B731054B52C Q35090423-CAF68FAD-6B48-4944-8AB0-676708C0CFA5 Q35184148-1851760A-2D0E-484F-BE86-9D7AB2BA2DAF Q35321539-E38F6BC0-3648-4F6E-BDEF-F91712382A59 Q35541293-7FD44FCF-F0B5-46E7-8438-6C538C917EE9 Q35545974-508C4DE3-A571-4A5F-9298-E80E6A6C7E58 Q35772596-E3E63AC2-1093-41B5-A288-AB5E3F4922E3 Q36330297-677D9117-D459-487F-8243-550FA3131F5D Q36462680-59EA0E29-B2BA-4F39-938E-7CEF4F5B9E49 Q36530573-FB03F217-F2BC-44B3-BD70-8E5EF0E7F917 Q37024947-A56ED984-193A-4AD2-A2D2-36C9351336DE Q37340312-2922BF0B-63AD-48BD-A353-99E20AC0AF73 Q37831912-CD3531AB-4ACC-4362-B23C-F7706FA493CC Q37842339-EA8F63CA-9514-4FE0-9C4E-9B3C07767F62 Q37862785-FE85A6F5-FF3F-4310-9AC5-F50A8901C913 Q37866811-53D7A795-6C91-4042-919E-7DE21B38FF8A Q37947768-F9C9D19C-617B-45BE-B60B-4CD586319A08 Q37980146-81797D0C-E844-4A8E-B8BD-0FE581687BF4 Q38050751-427F43D7-7275-430F-8216-3ECAB3EE2361 Q38053449-FBC2716C-BB7A-49A9-82C6-FDE91BD24C8C Q38122150-3F420D7A-C930-40FE-9302-3D881F2B0BBA Q38127470-751BD812-189D-4BC1-B1F6-7D52DC06E70C Q38202910-305CD499-9D51-41EE-B691-B3088811A56C Q38208226-3394CC51-0500-42ED-8803-68297D9659BC Q38283308-EB253C23-E38B-423F-97AB-C59424CC847D Q38881198-B6061C9D-31BE-435A-9357-1A6D2F297ABC

P2860

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

http://www.wikidata.org/entity/Q22241424

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@ast

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@en

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@en-gb

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@nl

type

label

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@ast

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@en

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@en-gb

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@nl

altLabel

Intravenous immunoglobulins as ...... rationale and current evidence

@en

prefLabel

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@ast

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@en

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@en-gb

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@nl

P1433

Q22241424-90BC12CB-B66C-4F72-A209-EE7C2571AF88

P1476

Q22241424-5E5D7DDA-E0F6-4208-BA61-214005D50C4A

P2093

Q22241424-1ED10CB9-143B-4474-9321-C432915DA71A

Q22241424-427868D3-0AAC-48F6-9D16-C31A7A10CA4D

Q22241424-E8385C42-55FC-4C00-A744-8C2C22D2A7E2

Q22241424-F7B30EB1-413F-42FB-B982-714F49F4FE12

P2860

Q22241424-0D583D50-CA88-4156-8009-E7B3D72F0E5F

Q22241424-13C65158-B6E0-4C37-8A0E-97477650DF26

Q22241424-78E03E6E-20C5-4B85-BE5A-C9E3CC615C5A

Q22241424-A51F0984-A307-43C5-9B12-1F715A28B039

Q22241424-FF264C48-30ED-4514-B560-D3053441C527

P2888

Q22241424-63F37128-831F-46A4-94E7-8FB9F909AC84

P304

Q22241424-9D87541D-0D18-4077-85F9-FD3DEB9454E5

P31

Q22241424-00A3C77B-A511-4038-AD37-791232FBEA08

P356

Q22241424-EAFD4EEC-2000-4CAA-AF97-AA80BBE557CB

P407

Q22241424-18209B0A-F696-42B4-B762-EF66B13F7095

P433

Q22241424-0B211D15-CEEC-44EC-A628-155EA14B7E59

P478

Q22241424-8C472A6C-F4C7-4BE5-BFC6-03394DBA9B39

P50

Q22241424-36632468-994A-4FF6-AA72-3C52E5B437BD

Q22241424-C31720FD-F393-40ED-924C-92F248607C07

Q22241424-F4C098DF-333E-4998-899E-441D95E94E88

P577

Q22241424-303C24D3-5B68-4E8D-B19F-B5C3DCA97F35

P6179

Q22241424-2A257DDF-CDB1-4F7D-BD44-C2FA95490C5B

P698

Q22241424-2306C9FC-57F2-4A68-ABA0-1C2BF782F6E5

P921

Q22241424-9CFAFCA7-45DD-4AA9-A555-952CCAE0232D

P356

11533070-000000000-00000

P1433

P1476

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

@en

P2093

Carmen Noelker

http://www.w3.org/2001/XMLSchema#string

Michael Bacher

http://www.w3.org/2001/XMLSchema#string

Refik Pul

http://www.w3.org/2001/XMLSchema#string

Yansheng Du

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.

Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies.

Complications of intravenous immune globulin treatment in neurologic disease.

Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients.

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

P2888

11533070-000000000-00000

P304

513-528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11533070-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang H. Oertel

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1048571828

http://www.w3.org/2001/XMLSchema#string

P698

20329802

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease